SOLENO THERAPEUTICS INC (SLNO) Stock Earnings Estimates
NASDAQ:SLNO • US8342033094
39.07 USD
+0.98 (+2.57%)
At close: Feb 27, 2026
39.07 USD
0 (0%)
Pre-Market: 3/2/2026, 9:19:29 AM
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 190.405M | 492.97M 158.91% | 760.14M 54.20% | |||
| EBITDA YoY % growth | -39.426M -75.70% | -185.684M -370.97% | 11.431M 106.16% | 246.87M 2,059.65% | 484.28M 96.17% | |
| EBIT YoY % growth | -41.384M -69.61% | -187.671M -353.49% | 9.414M 105.02% | 252.95M 2,586.96% | 491M 94.11% | |
| Operating Margin | N/A | N/A | 4.94% | 51.31% | 64.59% | |
| EPS YoY % growth | -2.97 10.54% | -4.26 -43.43% | 0.23 105.40% | 4.29 1,767.04% | 7.04 63.99% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.76 180.08% | 0.97 1,172.54% | 1.18 150.56% | 1.42 77.86% |
| Revenue Q2Q % growth | 97.86M | 110.63M 238.76% | 127.17M 92.63% | 146.08M 59.25% |
| EBITDA Q2Q % growth | 48.088M 206.30% | 66.739M 1,309.26% | 76.89M 225.63% | N/A |
| EBIT Q2Q % growth | 40.212M 187.91% | 53.896M 925.99% | 67.83M 206.85% | 83.32M 110.53% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2025 Q2Q % growth | 0.80 162.99% | 0.72 | 0.08 | 10.35% |
| Q3 2025 Q2Q % growth | 0.47 125.68% | 0.05 | 0.42 | 759.03% |
| Q2 2025 Q2Q % growth | -0.09 84.21% | -0.47 | 0.38 | 80.77% |
| Q1 2025 Q2Q % growth | -0.95 -61.02% | -0.95 | 0.00 | -0.42% |
| Q4 2024 Q2Q % growth | -1.27 -284.85% | -1.18 | -0.09 | -7.96% |
| Q3 2024 Q2Q % growth | -1.83 -92.63% | -0.64 | -1.19 | -186.49% |
| Q2 2024 Q2Q % growth | -0.57 29.63% | -0.61 | 0.04 | 6.60% |
| Q1 2024 Q2Q % growth | -0.59 32.95% | -0.38 | -0.21 | -57.04% |
| Q4 2023 Q2Q % growth | -0.33 43.10% | -0.28 | -0.05 | -18.37% |
| Q3 2023 Q2Q % growth | -0.95 -25.00% | -0.59 | -0.36 | -61.51% |
| Q2 2023 Q2Q % growth | -0.81 10.00% | -0.84 | 0.03 | 3.94% |
| Q1 2023 Q2Q % growth | -0.88 18.52% | -0.74 | -0.14 | -19.00% |
| Q4 2022 Q2Q % growth | -0.58 3.33% | -0.82 | 0.24 | 28.92% |
| Q3 2022 Q2Q % growth | -0.76 49.33% | -0.93 | 0.17 | 18.12% |
| Q2 2022 Q2Q % growth | -0.90 57.14% | -0.92 | 0.02 | 1.96% |
| Q1 2022 Q2Q % growth | -1.08 34.55% | -1.07 | -0.01 | -0.84% |
| Q4 2021 Q2Q % growth | -0.60 | -1.30 | 0.70 | 53.86% |
| Q3 2021 Q2Q % growth | -1.50 9.09% | -1.68 | 0.18 | 10.87% |
| Q2 2021 Q2Q % growth | -2.10 12.50% | -1.63 | -0.47 | -28.67% |
| Q1 2021 Q2Q % growth | -1.65 15.38% | -1.17 | -0.48 | -40.66% |
| Q4 2020 Q2Q % growth | -0.60 | -1.07 | 0.47 | 43.98% |
| Q3 2020 Q2Q % growth | -1.65 | -1.33 | -0.32 | -24.43% |
| Q2 2020 Q2Q % growth | -2.40 | -3.14 | 0.74 | 23.48% |
| Q1 2020 Q2Q % growth | -1.95 | -3.01 | 1.06 | 35.20% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2025 Q2Q % growth | 91.73M | 90.319M | 1.411M | 1.56% |
| Q3 2025 Q2Q % growth | 66.018M | 49.057M | 16.961M | 34.57% |
| Q2 2025 Q2Q % growth | 32.657M | 25.645M | 7.012M | 27.34% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 5.32% | 14.04% | 2.93% | 37.83% |
| Revenue | 5.11% | 7.31% | 1.27% | 19.66% |